TREATMENT OF HYPERTENSIVE PATIENTS WITH ALDOSTERONOMA AND ADRENAL HYPERPLASIA


Cite item

Full Text

Abstract

Arterial hypertension (AH) on the background of hyperaldosteronemia and decreased plasma renin activity (PRA) is etiologically linked to a wide range of tumors and non-neoplastic changes in the adrenal cortex. The treatment of hypertensive patients with low-renin hyperaldosteronism depends on the form of the disease diagnosed. Aldosteroma or unilateral (primary) adrenal hyperplasia require a surgical treatment. In idiopathic aldosteronism, pharmacological antihypertensive therapy with mineralocorticoid receptor antagonists (spironolactone, eplerenone) is effective. In patients with a rare form of familial hyperaldosteronism type 1, the use of low-dose glucocorticoids provides a correction of the clinical manifestations of disease. Differential diagnosis of hyperaldosteronism form allows to justify the appropriate method of treatment and overcome the refractory AH.

About the authors

N M Chikhladze

N M Chikhladze

References

  1. Ruilope LM. Aldosterone, Hypertension, and cardiovascular disease. Hypertension 2008;52:207.
  2. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation 2006;11:2572-74.
  3. Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertence 2000;14:311-15.
  4. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005;51:386-94.
  5. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-18.
  6. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;66:607-18.
  7. Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония (Диагностика и лечение) / АМН СССР. М., 1984. 136 с.
  8. Kaplan NM. Primary aldosteronism. In: Kaplan's clinical hypertension. Eighth edition, Lippincott Williams & Wilkins 2002;455-79.
  9. Ратнер Н.А. Первичный альдостеронизм, или синдром Конна: В кн. Артериальные гипертонии. 1974. С. 353-68.
  10. Calhonn DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronizm amang black and white subjects with resistant hypertension. Hypertension 2002;40:892-96.
  11. Funder JW, Carey RM, Fardella C, et al. Guidelines for management of patient with primary aldosteronism J Clin Endocrin Metab 2008;93:3266-81.
  12. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001;78:215-29.
  13. Rossi H, Kim A, Prinz RA. Prymary hyperaldosteronism in the era laparoscopic adrenalectomy. Am Surgeon 2002;68:253-6.
  14. Assalia A, Ganer M. Laparoscopic adrenalectomy. Brit J Surg 2004;91:1259-74.
  15. Shen WT, Lim RC, Siperstine AE, et al. Laparascopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Archiv surg 1999;134:628-31.
  16. РМОАГ, ВНОК. Диагностика и лечение артериальной гипертонии. Российские рекомендации (четвертый пересмотр). М., 2010.
  17. Chose RP, Hall PM, Bravo EL. Medical management of aldosterone-producting adenomas. Ann Intern Med 1999;131:105-08.
  18. Karagiannis A. Treatment of primary aldosteronism: where are we now? Rev Endocr Metab Disord 2011;12:15-20.
  19. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocr metab 2001;12:308-14.
  20. Bravo EH. Medical Management of Primary Aldosteronism. In.: Secondary Hypertension Ed. Mansoor GA, Humana Press. Totowa, New Jersey 2004;139-48.
  21. Karagiannins A, Tziomalos K, Kakafika A, et al. Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. Endocrine-Related Cancer 2008;15:693-700.
  22. Brown JJ, Davies DL, Ferriss JB, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 1972;2:729-34.
  23. Kremer D, Beevers DG, Brown JJ, et al. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. Clin Sci Mol Med 1973;45(1):213-18.
  24. Conn JW, Hinerman DL. Spironolactone - unduced inhibition of aldosterone biosynthesis in primary aldosteronism: morphological and functional studies. Metabolism 1977;26(12).
  25. Jeunemaitre X, Chateller G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essencial hypertension. Am J Cardiol 1987;60:820-25.
  26. Tunder JW. Eplerenone, a new mineralocorticoid antagonist: in vitro and in vivo studies. Cu. Opion Endocrinol Diabetes 2000;7:138-42.
  27. Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion Pharmacotherapy 2008;9(4):509-15.
  28. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61.
  29. Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 2002;88:475-80.
  30. Uchida T, Yamanaga K, Nishikava M, et al. Anti-aldosterone effect of torasemide. Eur J Pharmacol 1991;205:145-50.
  31. Гипертоническая болезнь и вторичные артериальные гипертонии (посвящается памяти Г.Г. Арабидзе) / Под ред. проф. И.Е. Чазовой. М., 2011. C. 138-58.
  32. Veglio F, Pinna G, Bisbocci D, et al. Efficacy of nicardipine slow release (SR) on hypertension, potassium balance and plasma aldosterone in idiopathic Aldosteronism. J Hum Hypertens 1990;4(5):579-82.
  33. Yokoyama T, Shimamoto K, Imura O. Mechanism of inhibition of aldosterone secretion by a Ca2+ channel blocker in patients with essential hypertension and patients with primary aldosteronism. Nihon Naibunpi Gakkai Zasshi 1995;71(7):1059-74.
  34. Kondo T, Goto R, Sonodo K, et al. Plasma rennin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine in hypertensive patients. Inter Med 2010;49:637-43.
  35. Dietz JD, Du S, Bolten CW, et al. A number of marketed dihidropyridine calcium channel blockers have mineralcorticoid receptor antagonist activity. Hypertension 2008;51:742-48.
  36. Kosaka H, Hirayama K, Yoda N, et al. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralcorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010;635:49-55.
  37. Bubbar CD, Blackburn DF, Wilson MP, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion. Ann Pharmacoter 2007;41(1):129-32.
  38. Griffing GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopatic hyperaldosteronism. J Clin Hypertens 1985;1(3):265-76.
  39. Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduses end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009;75(9):936-44.
  40. Amar L, Azizi M, Menard J, et al. Aldosteron synthase Inhibition with LCI699. A proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56:831-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies